Abciximab Antibody

SKU: orb1980599

Description

Abciximab (C7E3) is a chimeric monoclonal antibody that potently inhibits platelet aggregation and leukocyte adhesion by targeting glycoprotein IIb/IIIa, vitronectin, and Mac-1 receptors. It is widely used in cardiovascular research to study thrombosis and restenosis in both in vitro assays and in vivo animal models.

Research Area

Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	143653-53-6
MW	95.18 kDa
Purity	95.9% (SEC-HPLC)
Target	Integrin

Bioactivity

−

In Vivo	Effectively preventing neointimal hyperplasia, abciximab (C7E3) is administered at a dose of 0.25 mg/kg/day via intravenous infusion for 28 days.
In Vitro	Inhibiting platelet aggregation induced by physiologic and pathologic agonists, abciximab (C7E3) achieves this effect by binding to the platelet αIIbβ3 integrin. Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

C7E3, Abciximab, GPIIb/IIIa

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

Integrin

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols